@marietemara4.0: Why are the younger siblings always the tallest?😭 ##tall##family##height

Marie Temara
Marie Temara
Open In TikTok:
Region: US
Sunday 04 May 2025 21:32:22 GMT
990482
18391
396
353

Music

Download

Comments

legotron_builds
🇺🇲oliver🇺🇲 :
I noticed how your brothers aren't on the list of tallest people in the world
2025-05-10 19:26:19
195
marietemara4.0
Marie Temara :
Why are the younger siblings always the tallest?😅
2025-05-04 21:33:41
88
marietemara
Not Marie Temara :
The youngest brother is like 8’5
2025-05-04 21:35:02
7
chessmaster580
chessmaster :
It’s camera angles
2025-06-11 15:22:03
6
jimmybillybob4
jimmybillybob4 :
They r js closer to the camera
2025-06-14 03:09:49
6
georgesabiabboud
Georgesabiabboud :
Elias Saikaly is 187
2025-05-05 20:30:41
6
tocaboca_567l
toca boca_rp :
I am 67
2025-05-04 22:23:51
6
kidnamed_finger0
L.E.A.320 :
2025-06-11 20:46:11
1
zoran.milosavljevic
Zoki :
Im 204 cm 😂
2025-05-05 10:52:19
6
ferdi.kadioglu024
ferdi kadıoğlu :
Martinez go play for inter 🙏
2025-05-24 12:32:49
2
jakerealone
Jake Matthew :
these three are liars guys, if you search tallest man in the world, there's no exact guys in the list,
2025-05-24 04:22:12
5
fullgop13
John Mayer :
ага, а почему их в рейтинге самых высоких нет ?
2025-05-21 09:28:28
6
marietemara4.0
Marie Temara :
Who is the tallest in your family?🤔
2025-05-04 21:33:30
8
sadboytg92ms
Taz Garym :
160, 180 és 200 kb.
2025-05-07 08:29:50
2
dogo_jah
Dogo Jah :
height differences
2025-07-01 14:21:42
0
cy72257
CUÁNTO :
790
2025-09-24 03:23:53
0
user1346071199083
Sam :
You can see the platforms on the last guys shoes
2025-12-25 23:15:40
0
jenniferdewee
Jenn :
I am 178 cm tall with a size 6 shoe.
2025-07-01 19:50:14
0
twilliebillies
Twillie Billies :
I win... 3ft9 🙃
2025-07-08 21:01:48
0
To see more videos from user @marietemara4.0, please go to the Tikwm homepage.

Other Videos

Survodutide might be WAY more interesting than just another weight-loss drug. 🧬🔥 Everyone is watching the scale. I’m watching the liver. Survodutide is an investigational dual GLP-1 + glucagon receptor agonist and the Phase 3 data are getting seriously interesting. In people with obesity and at-risk fatty liver disease (MASLD), 84.2% of participants receiving survodutide achieved at least a 30% reduction in liver fat at 48 weeks versus 24.3% with placebo. Even crazier? About 6 out of 10 reached liver fat levels below 5%.  And in the separate obesity trial, survodutide produced up to 16.6% average weight loss over 76 weeks.  But here’s what fascinates me. Survodutide isn’t simply making people eat less. We’re manipulating the same brain-gut-metabolic signaling network involved in hunger, satiety, energy balance and metabolic regulation. Preclinical research published this year showed survodutide activating brain regions involved in appetite regulation through its GLP-1 activity.  So maybe the bigger conversation isn’t: “How much weight can this drug make someone lose?” Maybe it’s: “Why was the metabolic system dysregulated enough to produce obesity and fatty liver in the first place?” The drugs are getting better. Now our understanding of the biology needs to get better too. 🔬 Educational purposes only. Not medical advice. Survodutide remains investigational, and these results should not be interpreted as establishing it as an approved treatment. #Survodutide #GLP1 #Glucagon #WeightLoss #Obesity
Survodutide might be WAY more interesting than just another weight-loss drug. 🧬🔥 Everyone is watching the scale. I’m watching the liver. Survodutide is an investigational dual GLP-1 + glucagon receptor agonist and the Phase 3 data are getting seriously interesting. In people with obesity and at-risk fatty liver disease (MASLD), 84.2% of participants receiving survodutide achieved at least a 30% reduction in liver fat at 48 weeks versus 24.3% with placebo. Even crazier? About 6 out of 10 reached liver fat levels below 5%. And in the separate obesity trial, survodutide produced up to 16.6% average weight loss over 76 weeks. But here’s what fascinates me. Survodutide isn’t simply making people eat less. We’re manipulating the same brain-gut-metabolic signaling network involved in hunger, satiety, energy balance and metabolic regulation. Preclinical research published this year showed survodutide activating brain regions involved in appetite regulation through its GLP-1 activity. So maybe the bigger conversation isn’t: “How much weight can this drug make someone lose?” Maybe it’s: “Why was the metabolic system dysregulated enough to produce obesity and fatty liver in the first place?” The drugs are getting better. Now our understanding of the biology needs to get better too. 🔬 Educational purposes only. Not medical advice. Survodutide remains investigational, and these results should not be interpreted as establishing it as an approved treatment. #Survodutide #GLP1 #Glucagon #WeightLoss #Obesity

About